HCA Healthcare Stock: It Beat Q2 but CUT Its Guidance — So Why We Say BUY

HCA Healthcare (HCA) Q2 2026 — HCA Healthcare (HCA), the largest for-profit hospital operator in the U.S., delivered a headline-beating Q2 2026 — then CUT its full-year guidance. Q2 diluted EPS of $7.62 rose ~12% YoY (vs $6.83) on revenue of $20.23B (+8.7%) and adjusted EBITDA of $4.03B (+4.6%) — but the adjusted EBITDA margin compressed from 20.7% to 19.9%, and management LOWERED FY2026 guidance (EPS to $28.70–$30.50, net income to $6.3–$6.7B, adj EBITDA to $15.4–$16.1B), citing a worsening uninsured/payer-mix headwind now pegged at $1.0–$1.2B. A one-time ~$400M Florida Medicaid Supplemental catch-up roughly offset a ~$400M uninsured hit this quarter, flattering the print. The stock had already fallen ~32% from its $556 high to ~$377 (~13x earnings, ~9% FCF yield) and dropped ~7% on the July 14 preannouncement. Our leverage-adjusted owner-earnings DCF lands fair value near $400 — modestly above the price — and a buyback that has shrunk the share count ~20% in three years compounds per-share returns. Our call: BUY, 3/5. HCA Healthcare is the #1 for-profit hospital operator in America — a genuine fortress, running ~190 hospitals and 2,500+ sites of care across 20 states and the UK, led by CEO Sam Hazen — caught in a genuinely tricky moment. Q2 2026 looked strong on the surface: diluted EPS of $7.62 jumped ~12% YoY (vs $6.83), revenue rose 8.7% to $20.23B, and adjusted EBITDA reached $4.03B. But one layer down it sours: the adjusted EBITDA margin compressed from 20.7% to 19.9%, and management CUT full-year guidance — EPS to $28.70–$30.50, net income to $6.3–$6.7B, adj EBITDA to $15.4–$16.1B — as the uninsured/payer-mix headwind was revised WORSE, to $1.0–$1.2B for 2026. The root cause is policy: the enhanced ACA premium tax credits expired end-2025 and the new federal budget law is tightening Medicaid, pushing more patients into the uninsured bucket, with a bigger 2027 'cliff' the key risk. The quarter itself was flattered by a one-time ~$400M Florida Medicaid Supplemental catch-up that roughly offset a ~$400M uninsured hit. So why are we buyers? Because the market has already done a lot of the punishing: the stock fell ~32% from its $556 high to ~$377 (~13x earnings, ~9% FCF yield — the cheapest in years), and dropped ~7% on the July 14 preannouncement. Volumes are still healthy (same-facility admissions +2.5%, ER visits +3.6%), and a relentless buyback has cut the share count ~20% in three years — the real per-share growth engine, funded partly with debt on a leveraged, negative-book-equity balance sheet (~$49B net debt, 3.1x EBITDA). Our leverage-adjusted owner-earnings DCF (9/10/11% discount) lands fair value near $400 — modestly above the price — and the freshest post-preannouncement Street targets (Wells Fargo $369, BofA $370, Barclays $402) cluster right on it, even as a stale consensus average near $482 hasn't caught up. Our call: BUY, 3/5 — a de-rated cash machine where the fear is mostly priced in. Modest conviction, because the 2027 uninsured cliff is a real risk and this cut may not be the last. Add on the dips it keeps handing you in the $330s, and watch the 2027 guidance like a hawk. Not financial advice. THE CALL: BUY (3/5, A DE-RATED CASH MACHINE — A HEADLINE BEAT, A GUIDANCE CUT, AND THE FEAR MOSTLY PRICED IN) — base-case value ~$400 vs ~$377 today. What to watch: evidence the uninsured/payer-mix headwind is stabilizing rather than compounding — a 2027 outlook that holds, Medicaid supplemental programs proving durable, and margins bottoming — which would justify an upgrade toward 4/5; the risk to respect is the 2027 EPTC/health-insurance-exchange cliff deepening the uninsured hit (making this year's guidance cut a down-payment on a bigger one), or heavy leverage (~$49B net debt, 3.1x EBITDA, negative book equity) forcing the buyback to slow Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.